177 related articles for article (PubMed ID: 10831022)
1. Single-dose pharmacokinetics of methylphenidate in CYP2D6 extensive and poor metabolizers.
DeVane CL; Markowitz JS; Carson SW; Boulton DW; Gill HS; Nahas Z; Risch SC
J Clin Psychopharmacol; 2000 Jun; 20(3):347-9. PubMed ID: 10831022
[TBL] [Abstract][Full Text] [Related]
2. Absolute oral bioavailability of traxoprodil in cytochrome P450 2D6 extensive and poor metabolisers.
Taylor TJ; Diringer K; Russell T; Venkatakrishnan K; Wilner K; Crownover PH; Benincosa LJ; Gibbs MA
Clin Pharmacokinet; 2006; 45(10):989-1001. PubMed ID: 16984212
[TBL] [Abstract][Full Text] [Related]
3. The effects of CYP2D6 and CYP3A activities on the pharmacokinetics of immediate release oxycodone.
Samer CF; Daali Y; Wagner M; Hopfgartner G; Eap CB; Rebsamen MC; Rossier MF; Hochstrasser D; Dayer P; Desmeules JA
Br J Pharmacol; 2010 Jun; 160(4):907-18. PubMed ID: 20590587
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of CYP2D6 by quinidine and its effects on the metabolism of cilostazol.
Bramer SL; Suri A
Clin Pharmacokinet; 1999; 37 Suppl 2():41-51. PubMed ID: 10702886
[TBL] [Abstract][Full Text] [Related]
5. Influence of CYP2D6 polymorphism on the pharmacokinetics and pharmacodynamic of tolterodine.
Brynne N; Dalén P; Alván G; Bertilsson L; Gabrielsson J
Clin Pharmacol Ther; 1998 May; 63(5):529-39. PubMed ID: 9630826
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of methylphenidate and ritalinic acid in plasma correlations with exhaled breath and oral fluid in healthy volunteers.
Arvidsson M; Dahl ML; Beck O; Ackehed G; Nordin K; Rosenborg S
Eur J Clin Pharmacol; 2020 Feb; 76(2):229-237. PubMed ID: 31786618
[TBL] [Abstract][Full Text] [Related]
7. The influence of CYP2D6 polymorphism and quinidine on the disposition and antitussive effect of dextromethorphan in humans.
Capon DA; Bochner F; Kerry N; Mikus G; Danz C; Somogyi AA
Clin Pharmacol Ther; 1996 Sep; 60(3):295-307. PubMed ID: 8841152
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of dextromethorphan and metabolites in humans: influence of the CYP2D6 phenotype and quinidine inhibition.
Schadel M; Wu D; Otton SV; Kalow W; Sellers EM
J Clin Psychopharmacol; 1995 Aug; 15(4):263-9. PubMed ID: 7593709
[TBL] [Abstract][Full Text] [Related]
9. Involvement of CYP2D6 activity in the N-oxidation of procainamide in man.
Lessard E; Hamelin BA; Labbé L; O'Hara G; Bélanger PM; Turgeon J
Pharmacogenetics; 1999 Dec; 9(6):683-96. PubMed ID: 10634131
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of debrisoquine hydroxylation with quinidine in subjects with three or more functional CYP2D6 genes.
Dalén P; Dahl M; Andersson K; Bertilsson L
Br J Clin Pharmacol; 2000 Feb; 49(2):180-4. PubMed ID: 10671914
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension.
Zineh I; Beitelshees AL; Gaedigk A; Walker JR; Pauly DF; Eberst K; Leeder JS; Phillips MS; Gelfand CA; Johnson JA
Clin Pharmacol Ther; 2004 Dec; 76(6):536-44. PubMed ID: 15592325
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication.
Kirchheiner J; Schmidt H; Tzvetkov M; Keulen JT; Lötsch J; Roots I; Brockmöller J
Pharmacogenomics J; 2007 Aug; 7(4):257-65. PubMed ID: 16819548
[TBL] [Abstract][Full Text] [Related]
13. A single-dose, two-way crossover, bioequivalence study of dexmethylphenidate HCl with and without food in healthy subjects.
Teo SK; Scheffler MR; Wu A; Stirling DI; Thomas SD; Stypinski D; Khetani VD
J Clin Pharmacol; 2004 Feb; 44(2):173-8. PubMed ID: 14747426
[TBL] [Abstract][Full Text] [Related]
14. The gastroprokinetic and antiemetic drug metoclopramide is a substrate and inhibitor of cytochrome P450 2D6.
Desta Z; Wu GM; Morocho AM; Flockhart DA
Drug Metab Dispos; 2002 Mar; 30(3):336-43. PubMed ID: 11854155
[TBL] [Abstract][Full Text] [Related]
15. The roles of CYP2D6 and stereoselectivity in the clinical pharmacokinetics of chlorpheniramine.
Yasuda SU; Zannikos P; Young AE; Fried KM; Wainer IW; Woosley RL
Br J Clin Pharmacol; 2002 May; 53(5):519-25. PubMed ID: 11994058
[TBL] [Abstract][Full Text] [Related]
16. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen.
Goetz MP; Knox SK; Suman VJ; Rae JM; Safgren SL; Ames MM; Visscher DW; Reynolds C; Couch FJ; Lingle WL; Weinshilboum RM; Fritcher EG; Nibbe AM; Desta Z; Nguyen A; Flockhart DA; Perez EA; Ingle JN
Breast Cancer Res Treat; 2007 Jan; 101(1):113-21. PubMed ID: 17115111
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of methylphenidate after oral administration of two modified-release formulations in healthy adults.
Markowitz JS; Straughn AB; Patrick KS; DeVane CL; Pestreich L; Lee J; Wang Y; Muniz R
Clin Pharmacokinet; 2003; 42(4):393-401. PubMed ID: 12648029
[TBL] [Abstract][Full Text] [Related]
18. Effect of low-dose ritonavir (100 mg twice daily) on the activity of cytochrome P450 2D6 in healthy volunteers.
Aarnoutse RE; Kleinnijenhuis J; Koopmans PP; Touw DJ; Wieling J; Hekster YA; Burger DM
Clin Pharmacol Ther; 2005 Dec; 78(6):664-74. PubMed ID: 16338282
[TBL] [Abstract][Full Text] [Related]
19. Genetic polymorphisms and drug interactions modulating CYP2D6 and CYP3A activities have a major effect on oxycodone analgesic efficacy and safety.
Samer CF; Daali Y; Wagner M; Hopfgartner G; Eap CB; Rebsamen MC; Rossier MF; Hochstrasser D; Dayer P; Desmeules JA
Br J Pharmacol; 2010 Jun; 160(4):919-30. PubMed ID: 20590588
[TBL] [Abstract][Full Text] [Related]
20. Effect of CYP2D6 polymorphism on pharmacokinetics of a novel ACAT inhibitor, pactimibe and its unique metabolite, R-125528.
Kotsuma M; Tokui T; Freudenthaler S; Nishimura K
Int J Clin Pharmacol Ther; 2008 Nov; 46(11):545-55. PubMed ID: 19000552
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
